Forte’s FB-401 Fails to Meet Primary Endpoints in P-II Clinical Trial For the Treatment of Atopic Dermatitis Published: Sept 3, 2021 | Tags: Forte, FB-401, P-II, Clinical Trial, Atopic Dermatitis […]readmore
Tags : Evotec
Shots: Evotec receives $20M as an option fee & is eligible to receive ~$250M as milestones along with royalties. BMS will be responsible for further development & commercialization of a […]readmore
BMS’ Opdivo + Yervoy and Onureg Receive EC’s CHMP Positive Opinion for MPM and AML Published: Apr 23, 2021 | Tags: BMS, Opdivo, Yervoy, Onureg, Receive, EC, CHMP, Positive Opinion, […]readmore
Shots: Evotec to receive a up front as well as research funding for biomarker development and CMC and is eligible to receive $361.21M as clinical & commercial milestones along with […]readmore
Evotec and Exscientia Initiate Human Clinical Trials of their Novel Immuno-Oncology Drug Published: Apr 9, 2021 | Tags: Evotec and Exscientia, Initiate, Human Clinical Trials, Novel, Immuno-Oncology Drug PlantForm Signs […]readmore
Shots: Evotec to receive research funding and will be eligible for $160M/program as discovery, pre/ clinical, a commercial milestone along with royalties on sales of product emerges from the collaboration […]readmore
Visby’s POC COVID-19 Test Receives the US FDA’s EUA for Use in CLIA Waived Settings Published: Feb 12, 2020 | Tags: Visby, POC, COVID-19, Test, Receives, US, FDA, EUA, Use, CLIA, […]readmore
Shots: Evotec to receive milestones, royalties, and a founding equity stake in all Related Sciences assets developed under the collaboration Evotec and Related Sciences will jointly discover & develop a […]readmore
Almirall and Tyris Collaborate to Develop Next Generation Gene Therapies Published: Jan 7, 2020 | Tags: Almirall, Tyris, Collaborate, Develop, Next Generation, Gene Therapies Sarepta Reports Mixed Results of SRP-9001 […]readmore
Shots: Evotec has received $6M as milestones under its iPSC-based neuroscience alliance with BMS. The milestones follow BMS’ decision to add another drug discovery project to the partnership’s portfolio In […]readmore